Bausch + Lomb Says Dual-Action Dry Eye Drop Missed Phase 2 Primary Endpoint At Day 29, Met Secondary Endpoint At Day 15; Advancing To Phase 3 With Day 15 Primary Endpoint
Share
Why It Matters
Bausch + Lomb's new eye-drop medicine didn't work as well as hoped at one time point, but worked better at an earlier time point. The company is still moving forward with more testing, which shows they think it could still help people.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.